Webinar: Dyne Therapeutics — Topline Results from Phase 1/2 DELIVER Trial

Dyne Therapeutics joined PPMD for a community webinar on January 28th at 1:00 PM ET. The webinar features a presentation with Dr. Doug Kerr, Dyne's Chief Medical Officer, who shares topline results from the DELIVER clinical trial, along with new long-term data showing sustained benefits out to 24 months. DELIVER is Dyne’s global, randomized, placebo-controlled, double-blind, Phase 1/2 trial that evaluated the safety, tolerability and efficacy of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy who have mutations in the DMD gene that are amenable to exon 51 skipping.